share_log

信达证券4月18日发布研报称，给予爱博医疗（688050.SH）买入评级。评级理由主要包括：1）年报业绩与快报一致；2）一季报收入利润高增；3）23年手术业务国内高景气+出海快速扩张，24年国采即将实施；4）隐形眼镜业务剑指行业龙头，成为公司第三增长曲线；5）持续研发投入，多款重点产品值得期待。（每日经济新闻）

Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly r

Zhitong Finance ·  Apr 18 15:17
Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly report's revenue and profit increased; 3) the surgical business was booming domestically and rapidly expanded overseas in '23, and the national procurement is about to be implemented; 4) the contact lens business is the leader in the industry and has become the company's third growth curve; 5) continuous investment in R&D, and various key products are worth looking forward to. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment